Abstract
Research question Is it possible to identify accurately the optimal first dose of FSH in controlled ovarian stimulation (COS) by means of a machine learning (ML) model?
Design Observational study (2011 to 2021) including first In Vitro Fertilization (IVF) cycles with own oocytes. 2713 patients from five private reproductive centers were included in the development phase of the model (2011 to 2019), and 774 in the validation phase (2020 to 2021). Predictor variables included: age, Body Mass Index (BMI), Antimullerian Hormone (AMH), Antral Follicle Count (AFC), and previous live births. Performance of the developed model was measured with a proposed score based on the number of MII retrieved and the dose received and/or recommended.
Results The cycles included were from women 37.2±4.9 years old [18-45], with a BMI of 23.7±4.2, AMH of 2.4±2.3, AFC of 11.8±7.7; and an average number of MII obtained 7.2±5.3. The model reached a mean performance score of 0.87 (95% CI 0.86 to 0.88) in the development phase; this value was significantly better than the one for the doses prescribed by the clinicians for the same patients (0.83 [0.82, 0.84]; p-value= 2.44 e-10). The mean performance score of the model recommendations was 0.89 (95% CI 0.88 to 0.90) in the validation phase, also significantly better than clinicians (0.84 [0.82, 0.86]; p-value = 3.81 e-05). With these results the model was shown to surpass the performance of the standard practice.
Conclusion(s) The ML model developed could be deployed as a training and learning tool for new clinicians and serve as quality control for experienced ones; further, it could be used as second opinion, for instance by providing information in peer-to-peer case discussions.
Key Message A Machine Learning model was trained to recommend first FSH doses for ovarian stimulation. When compared to clinicians the model developed had consistently better performance scores. The model could be used as a second opinion and as learning tool for new clinicians; to avoid as many non-optimal outcomes as possible.
- Ovarian Stimulation
- Artificial Intelligence
- Machine Learning
- Prediction
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Doctorat Industrial funded by Generalitat de Catalunya [DI-2019-24], by project CI-SUSTAIN funded by the Spanish Ministry of Science and Innovation [PID2019-104156GB-I00], and by intramural funding by Clinica Eugin-Eugin Group.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee for Research of Eugin gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript